A longitudinal study across two major U.S. health databases found nucleoside reverse transcriptase inhibitors to be associated with reduced Alzheimer's disease incidence.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
FDA approves Brekiya®, a dihydroergotamine mesylate autoinjector for the acute treatment of migraine with or without aura and cluster headaches in adults.
Stigmatizing language on transplant websites may deter patients with alcohol use disorder and alcohol-associated liver disease from seeking necessary medical care.